NextCell Pharma AB (SE:NXTCL)

:NXTCL

NXTCL

NextCell Pharma AB

RESEARCH TOOLSreports

Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr116.96M

Enterprise Valuekr86.86M

Total Cash (Recent Filing)kr32.33M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding111,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr16.60M

Bulls Say, Bears Say

Bulls Say

Zero Debt / Conservative Balance SheetMaintaining zero reported debt materially lowers financial and refinancing risk for a cash-burning biotech. This durable structural strength preserves flexibility to pursue clinical programs or partnerships without fixed interest burdens, improving resilience across 2-6 months of execution risk.

Multi-year Revenue GrowthSustained top-line growth over multiple years indicates genuine commercial traction or expanding program activity rather than a one-off spike. Durable revenue expansion supports eventual operating leverage once development costs stabilize, and underpins longer-term scalability of the cell-therapy business model.

Improving Free Cash Flow TrendA meaningful improvement in free cash flow growth versus the prior year signals operating efficiency gains or better revenue mix. While FCF remains negative, a sustained improvement trend reduces cumulative burn, lengthens runway and lowers structural reliance on frequent external financing over the medium term.

Bears Say

Large, Persistent Cash BurnDeep negative operating and free cash flow across the trailing twelve months indicates the company must repeatedly access external capital to fund operations. That persistent burn is a durable constraint: it increases financing risk, forces dilution or strategic compromises and limits ability to self-fund clinical or commercial expansion.

Consistently Negative Gross Margins And LossesNegative gross margins over multiple periods imply structural cost or pricing mismatches for core products/programs. Persistent unprofitability at the gross and net levels means the company must materially change cost structures or revenue model to reach sustainable margins, a non-trivial long-term operational challenge.

Declining Equity And Dilution RiskMaterial declines in equity reflect accumulated losses and prior financing events. With continued cash burn, the company faces a durable risk of further equity raises that dilute existing holders and reduce per-share value, while also shrinking the balance-sheet buffer for clinical setbacks or delays.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr116.96M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 71 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -kr0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.092.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.206%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.